|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
WANG CHIEN CHIH | KAN PEI | KAN PEI | (02)27827561 | 3F.-3, No. 66, Sanchong Rd., Nangang Dist.,Taipei City 115602 , Taiwan (R.O.C.) | 2024/03/26 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Pharmosa Biopharm Inc.(PBI) is a world-class biotechnology company focusing on developing a new drug by exploiting our proprietary formulation and manufacturing technology. With regional/global strategic partnerships,we commercialize our product through 505(b)2 or hybrid applications to regulatory authorities. Our Vision: We strive for excellence in order to improve quality of life for people through innovation and sustained quality. Our Mission: We expand the potential of existing drugs by exploiting innovative delivery formulations and medical devices,then bringing the combined medicines to patients and healthcare providers. |
Market Information ( 2024/05/13 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
359.465 | 72.60 | 69.00 | 71.50 | 2.00 | 332 | N/A | N/A | ||||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/05/13) |
TPEx measures adopted (2024/05/13) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |